Search

Your search keyword '"Grand-Maison F."' showing total 78 results
Start Over Author "Grand-Maison F."
78 results on '"Grand-Maison F."'

2. Long-term outcomes in patients presenting with optic neuritis: analyses of the MSBase registry

Author

Horakova, D., Granella, F., Grand-Maison, F., ÖZAKBAŞ, SERKAN, Bergamaschi, R., Ampapa, R., Alroughani, R., Liu, M., Kenney, R., Turkoglu, R., Terzi, M., Spitaleri, D. L. A., Soysal, A., Sola, P., Preiningerova, J. Lizrova, Patti, F., Onofrj, M., Lugaresi, A., Kalincik, T., Ayuso, G. Izquierdo, Galetta, S., Balcer, L., Kister, I., Spelman, T., Madueno, S. Eichau, Ferraro, D., Boz, C., Butzkueven, H., Gomez, J. Cabrera, Cartechini, E., Thorpe, L., Saidha, S., and Van Pesch, V.

Published
2021

3. Real-world experience with cladribine in the MSBase Registry

Author

Prevost, J., Van der Walt, A., Kalincik, T., Grand-Maison, F., McCombe, P., Butler, E., Lechner-Scott, J., di Cantogno, E. Verdun, Van Hijfte, L., Laureys, G., Ozakbas, SERKAN, Girard, M., Prat, A., Hodgkinson, S., Spelman, T., Butzkueven, H., Van Pesch, V., Macdonell, R., Oh, J., Alroughani, R., Grammond, P., Sanchez-Menoyo, J. -L., Terzi, M., Duquette, P., Madueno, S. Eichau, Izquierdo, G., Buzzard, K., and Skabina, O.

Published
2021

4. BREMSO: a simple score to predict early the natural course of multiple sclerosis

Author

Bergamaschi, R., Montomoli, C., Mallucci, G., Lugaresi, A., Izquierdo, G., GrandʼMaison, F., Duquette, P., Shaygannejad, V., Alroughani, R., Grammond, P., Boz, C., Iuliano, G., Zwanikken, C., Petersen, T., Lechner-Scott, J., Hupperts, R., Butzkueven, H., Pucci, E., Oreja-Guevara, C., Cristiano, E., Amato, Pia M. P., Havrdova, E., Fernandez-Bolanos, R., Spelman, T., and Trojano, M.

Published
2015
Full Text
View/download PDF

7. Real-world experience with ocrelizumab in the msbase registry

Author

Butzkueven, H., Spelman, T., Ozakbas, S., Kalincik, T., Boz, C., Buzzard, K., Skibina, O., Alroughani, R., Karabudak, R., Walt, A., Lechner-Scott, J., Hodgkinson, S., Laureys, G., Hijfte, L., Terzi, M., Butler, E., Macdonell, R., Patti, F., Pesch, V., Slee, M., Barnett, M., Grammond, P., Prevost, J., Grand-Maison, F., Taylor, B., Allan Kermode, Mccombe, P., Duquette, P., Prat, A., Girard, M., Eichau Madueno, S., Izquierdo, G., Soysal, A., Sanchez-Menoyo, J. L., Sotoca, J., Muros-Le Rouzic, E., and Dirks, P.

Published
2020

8. Pregnancy in a modern day multiple sclerosis cohort: predictors of postpartum relapse and disability progression

Author

Jokubaitis, V., Yeh, W., Widyastuti, P., Stankovich, J., Gresle, M., Havrdova, E. Kubala, Horakova, D., Vodehnalova, K., Ozakbas, S., Madueno, S. Eichau, Duquette, P., Kalincik, T., Patti, F., Boz, C., Terzi, M., Yamout, B., Lechner-Scott, J., Sola, P., Skibina, O., Barnett, M., Onofrj, M., Sa, M. J., Mccombe, P., Grammond, P., Ampapa, R., Grand Maison, F., Bergamaschi, R., Spitaleri, D., Pesch, V., Cartechini, E., Hodgkinson, S., Soysal, A., Saiz, A., Uher, T., Maimone, D., Turkoglu, R., Hupperts, R., Amato, M. P., Granella, F., Eva Kubala Havrdova, Altintas, A., Macdonell, R., Castillo-Trivino, T., Butzkueven, H., Alroughani, R., and Walt, A.

Published
2020

9. Pregnancy in a modern day multiple sclerosis cohort: predictors of relapse during pregnancy

Author

Yeh, W., Widyastuti, P., Walt, A., Stankovich, J., Gresle, M., Havrdova, E., Horakova, D., Vodehnalova, K., Ozakbas, S., Eichau, S., Duquette, P., Kalincik, T., Patti, F., Boz, C., Terzi, M., Yamout, B., Lechner-Scott, J., Sola, P., Skibina, O., Barnett, M., Onofrj, M., Sa, M. J., Mccombe, P., Grammond, P., Ampapa, R., Grand Maison, F., Bergamaschi, R., Spitaleri, D., Pesch, V., Cartechini, E., Hodgkinson, S., Soysal, A., Saiz, A., Uher, T., Maimone, D., Turkoglu, R., Hupperts, R., Amato, M. P., Granella, F., Eva Kubala Havrdova, Altintas, A., Macdonell, R., Castillo-Trivino, T., Butzkueven, H., Alroughani, R., and Jokubaitis, V.

Published
2020

10. Real-world experience with cladribine tablets in the MSBase registry.

Author

Butzkueven H., Spelman T., Hodgkinson S., Kalincik T., Buzzard K., Skabina O., Madueno S.E., Ayuso G.I., Van Der Walt A., Grand-Maison F., Butler E., Prevost J., McCombe P., Oh J., MacDonell R., Lechner-Scott J., Van Pesch V., Duquette P., Prat A., Girard M., Kermode A., Fabris J., Butzkueven H., Spelman T., Hodgkinson S., Kalincik T., Buzzard K., Skabina O., Madueno S.E., Ayuso G.I., Van Der Walt A., Grand-Maison F., Butler E., Prevost J., McCombe P., Oh J., MacDonell R., Lechner-Scott J., Van Pesch V., Duquette P., Prat A., Girard M., Kermode A., and Fabris J.

Abstract

Objective: We analysed the cladribine treatment experience in the MSBase registry. We described baseline characteristics, treatment pathways, and relapse and discontinuation outcomes in patients with >=6 months follow-up data from cladribine initiation. Background(s): Cladribine tablets are approved for treatment of multiple sclerosis (MS) in many jurisdictions. Real-world outcomes data is very limited. Design/Methods: We performed a secondary data analysis using MSBase Registry data of patients with a confirmed diagnosis of MS and newly treated with cladribine tablets after regulatory approval. Descriptive statistics were used to analyse baseline patient characteristics recorded With in 3 months prior to cladribine tablets initiation, including demographics, disease course and duration, prior disease modifying drugs (DMD), and Expanded Disability Status Scale (EDSS). Result(s): As of the 4th June 2020, MSBase included 660 patients treated with cladribine from 9 countries, mainly from Australia and Europe. A total of 576 met all inclusion criteria. These included 496 relapsing-remitting MS (RRMS) patients. In these, median age at cladribine tablets start was 45 years and median disease duration since clinically isolated syndrome was 12.6 years. Median EDSS at cladribine tablets start was 2.5. Around 13% of all RRMS patients initiated cladribine tablets as first line therapy. Of all RRMS patients switching to cladribine tablets with a treatment gap of <6 months, the most common immediate prior DMDs were fingolimod (17%), followed by natalizumab, teriflunomide and dimethylfumarate (all appx. 10%). Total follow-up time was 340 patient-years. Annualised relapse rate (ARR) on cladribine tablets was 0.12 (95%CI 0.09-0.17), compared to a pre-cladribine ARR of 0.38. Treatment persistence was 95% after 12 months (95%CI 91-98%), and 92% after 24 months (95%CI 87-96%). Conclusion(s): This study characterizes RRMS patients treated with cladribine tablets in a realworld clinic s

Published
2021

11. Real-world experience with ocrelizumab in the msbase registry.

Author

Hodgkinson S., Spelman T., Ozakbas S., Kalincik T., Boz C., Buzzard K., Skibina O., Alroughani R., Karabudak R., Van Der Walt A., Lechner-Scott J., Taylor B., Kermode A., Mccombe P., Duquette P., Prat A., Girard M., Eichau Madueno S., Izquierdo G., Soysal A., Sanchez-Menoyo J.L., Sotoca J., Muros-Le Rouzic E., Dirks P., Butzkueven H., Laureys G., Van Hijfte L., Terzi M., Butler E., Macdonell R., Patti F., Van Pesch V., Slee M., Barnett M., Grammond P., Prevost J., Grand-Maison F., Hodgkinson S., Spelman T., Ozakbas S., Kalincik T., Boz C., Buzzard K., Skibina O., Alroughani R., Karabudak R., Van Der Walt A., Lechner-Scott J., Taylor B., Kermode A., Mccombe P., Duquette P., Prat A., Girard M., Eichau Madueno S., Izquierdo G., Soysal A., Sanchez-Menoyo J.L., Sotoca J., Muros-Le Rouzic E., Dirks P., Butzkueven H., Laureys G., Van Hijfte L., Terzi M., Butler E., Macdonell R., Patti F., Van Pesch V., Slee M., Barnett M., Grammond P., Prevost J., and Grand-Maison F.

Abstract

Background: Ocrelizumab (OCR) is a humanised anti-CD20+ monoclonal antibody approved for the treatment of primary progressive multiple sclerosis (PPMS), and relapsing forms of MS, including both relapsing-remitting (RRMS) and secondary progressive MS (SPMS) with relapses. Objective(s): In a real-world setting, to describe 1) baseline characteristics of patients with MS treated with OCR, 2) treatment pathway across lines of therapy up to initiation of OCR, and 3) initial clinical experience in patients with >=6 months follow-up data from OCR initiation. Method(s): Secondary data analysis using MSBase Registry data including patients with a confirmed diagnosis of MS and started OCR therapy within 3 months prior to or at time of MSBase eligible/ initial visit. Descriptive statistics were used to analyze baseline patient characteristics' recorded within 3 months of OCR initiation, including demographics, disease course and duration, prior disease modifying therapies (DMT), and EDSS. Occurrence of relapse was analyzed in patients with >=6 months follow-up data from OCR initiation. Result(s): As of 4th June 2020, MSBase included 2531 patients newly treated with OCR, of whom 1679 had an EDSS evaluation within 3 months of OCR start. There were 1185 patients with RRMS, 236 with SPMS, and 183 with PPMS. Median age at OCR initiation was 41.9 years, 49.5 years, to 50.1 years in RRMS, SPMS, and PPMS, respectively. Mean disease duration from symptom onset up to OCR initiation was longer in SPMS (19.7 years) than in RRMS (10.6 years) and PPMS (9.7 years). OCR was initiated as first line therapy in 17.5%, 5.5%, and 54.2% of RRMS, SPMS, and PPMS patients respectively. Most frequent previous DMT's in RRMS were fingolimod (25.7%) and natalizumab (23.5%). 693 patients with RRMS had >=6 months followup during OCR exposure. Of these, 643 remained relapse free (93%; 95% CI 86.0, 100.0) over a mean OCR exposure of 1.23 years. The annualized relapse rate (ARR) was 0.08 (95% CI 0.06- 0.10)

Published
2021

12. Real-world experience with cladribine tablets in the msbase registry.

Author

Girard M., Duquette P., Prat A., Kermode A., Fabris J., Butzkueven H., Spelman T., Hodgkinson S., Kalincik T., Buzzard K., Skibina O., Eichau Madueno S., Izquierdo G., Van Der Walt A., Grand-Maison F., Butler E., Prevost J., Mccombe P., Oh J., Macdonell R., Lechner-Scott J., Van Pesch V., Girard M., Duquette P., Prat A., Kermode A., Fabris J., Butzkueven H., Spelman T., Hodgkinson S., Kalincik T., Buzzard K., Skibina O., Eichau Madueno S., Izquierdo G., Van Der Walt A., Grand-Maison F., Butler E., Prevost J., Mccombe P., Oh J., Macdonell R., Lechner-Scott J., and Van Pesch V.

Abstract

Background: Cladribine tablets are approved for treatment of multiple sclerosis (MS) in many jurisdictions. Real-world outcomes data is very limited. Objective(s): We analysed the cladribine treatment experience in the MSBase registry. We described baseline characteristics, treatment pathways, and relapse and discontinuation outcomes in patients with >=6 months follow-up data from cladribine initiation. Method(s): We performed a secondary data analysis using MSBase Registry data of patients with a confirmed diagnosis of MS and newly treated with cladribine tablets after regulatory approval. Descriptive statistics were used to analyze baseline patient characteristics recorded within 3 months prior to cladribine tablets initiation, including demographics, disease course and duration, prior disease modifying drugs (DMD), and Expanded Disability Status Scale (EDSS). Result(s): As of the 4th June 2020, MSBase included 660 patients treated with cladribine from 9 countries, mainly from Australia and Europe. A total of 576 met all inclusion criteria. These included 496 relapsing-remitting MS (RRMS) patients. In these, median age at cladribine tablets start was 45 years and median disease duration since clinically isolated syndrome was 12.6 years. Median EDSS at cladribine tablets start was 2.5. Around 13% of all RRMS patients initiated cladribine tablets as first line therapy. Of all RRMS patients switching to cladribine tablets with a treatment gap of <6 months, the most common immediate prior DMDs were fingolimod (17%), followed by natalizumab, teriflunomide and dimethylfumarate (all appx. 10%). Total follow- up time was 340 patient-years. Annualised relapse rate (ARR) on cladribine tablets was 0.12 (95%CI 0.09-0.17), compared to a pre-cladribine ARR of 0.38. Treatment persistence was 95% after 12 months (95%CI 91-98%), and 92% after 24 months (95%CI 87-96%). Conclusion(s): This study characterizes RRMS patients treated with cladribine tablets in a real-world clinic setti

Published
2021

13. Real-world experience with cladribine in the MSBase Registry.

Author

Butzkueven H., Spelman T., Hodgkinson S., Eichau Madueno S., Izquierdo G., Buzzard K., Skabina O., Van Der Walt A., Kalincik T., Grand-Maison F., McCombe P., Butler E., Prevost J., Van Pesch V., Ozakbas S., Macdonell R., Oh J., Alroughani R., Lechner-Scott J., Grammond P., Sanchez-Menoyo J.-L., Terzi M., Duquette P., Prat A., Girard M., Laureys G., Van Hijfte L., Verdun Di Cantogno E., Butzkueven H., Spelman T., Hodgkinson S., Eichau Madueno S., Izquierdo G., Buzzard K., Skabina O., Van Der Walt A., Kalincik T., Grand-Maison F., McCombe P., Butler E., Prevost J., Van Pesch V., Ozakbas S., Macdonell R., Oh J., Alroughani R., Lechner-Scott J., Grammond P., Sanchez-Menoyo J.-L., Terzi M., Duquette P., Prat A., Girard M., Laureys G., Van Hijfte L., and Verdun Di Cantogno E.

Abstract

Introduction: Cladribine tablets are approved for relapsing multiple sclerosis (RMS) treatment in many jurisdictions. MSBase investigators are committed to characterising real-world longitudinal treatment outcomes using this registry data. Objective(s): To describe cladribine treatment outcomes in the MSBase cohort. These include baseline characteristics, treatment pathways, discontinuation rate, and relapse outcomes. Method(s): We extracted from the MSBase registry data for all patients with a confirmed diagnosis of MS who were newly treated with cladribine tablets. Descriptive statistics were used to analyse baseline patient characteristics recorded within 3 months prior to cladribine tablets initiation, including demographics, disease course and duration, prior disease modifying drugs (DMD), and EDSS. Relapse and discontinuation outcomes were described in patients with a minimum 6 month observation period. Result(s): As of 3rd March 2021, a total of 782 patients, predominantly from Australia, Canada and Spain, were included. 696 were relapsing-remitting MS (RRMS) patients. The median age of cladribine tablet start was 43.8 years and median disease duration was 11.8 years. Median EDSS at cladribine initiation was 2 (IQR 1.5,4). 13.3% of all RRMS patients initiated cladribine as first line therapy. Of all RRMS patients switching to cladribine tablets with a treatment gap of <6 months, the most common immediate prior DMD was Fingolimod (15%), followed by Natalizumab (10%) and Teriflunomide (9.5%). Total follow-up time was 629 patientyears. Annualised relapse rate (ARR) on cladribine tablets was 0.11 (95% CI 0.09-0.14) compared to a 12-month pre-cladribine ARR of 0.41. Treatment persistence was 96% at 12 months (95% CI 0.94-0.98) and 90% after 24months (95% CI 0.85-0.94). Conclusion(s): The growing MSBase real-world cladribine cohort shows excellent outcomes to date. The most common switches to cladribine are from other high-efficacy DMTs such as Natalizumab or Fingo

Published
2021

14. Fluctuations of MS births and UV-light exposure

Author

Verheul, F., Smolders, J., Trojano, M., Lepore, V., Zwanikken, C., Amato, M. P., GrandʼMaison, F., Butzkueven, H., Marrosu, M., Duquette, P., Comi, G., Izquierdo, G., Grammond, P., Lus, G., Petersen, T., Bergamaschi, R., Giuliani, G., Boz, C., Coniglio, G., Van Pesch, V., Lechner-Scott, J., Cavalla, P., Granella, F., Avolio, C., Fiol, M., Poehlau, D., Saladino, M. L., Gallo, P., Deri, N., Oleschko Arruda, W., Paine, M., Ferro, M., Barnett, M., Cabrera-Gomez, J. A., Slee, M., Moore, F., Shaw, C., Petkovska-Boskova, T., Rutherford, M., Engelsen, O., Damoiseaux, J., and Hupperts, R.

Published
2013
Full Text
View/download PDF

15. of Therapeutic Lag in Relapsing Multiple Sclerosis

Author

Izanne Roos, Frascoli, F., Horakova, D., Havrdova, E. Kubala, Trojano, M., Izquierdo, G., Eichau, S., Patti, F., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grammond, P., Ozakbas, S., Sola, P., Ferraro, D., Bergamaschi, R., Cartechini, E., Sa, M. Jose, Boz, C., Grand Maison, F., Lechner-Scott, J., Terzi, M., Granella, F., Alroughani, R., Iuliano, G., Hupperts, R., Spitaleri, D., Pesch, V., Soysal, A., Prevost, J., Olascoaga, J., Aguera-Morales, E., Turkoglu, R., Slee, M., Ramo-Tello, C., Sidhom, Y., Gouider, R., Mccombe, P., Butzkueven, H., Malpas, C., and Kalincik, T.

Published
2020

16. Therapeutic lag in relapsing multiple sclerosis

Author

Roos, I., Frascoli, F., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Patti, F., Onofr, M., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Ozakbas, S., Grammond, P., Sola, P., Ferraro, D., Bergamaschi, R., Boz, C., Cartechini, E., Sa, M. J., Terzi, M., Alroughani, R., Grand Maison, F., Granella, F., Iuliano, G., Hupperts, R., Lechner-Scott, J., Spitaleri, D., Pesch, V., Soysal, A., Prevost, J., Aguera-Morales, E., Olascoaga, J., Recai Turkoglu, Sidhom, Y., Gouider, R., Wijmeersch, B., Butzkueven, H., Malpas, C., and Kalincik, T.

Published
2019

17. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS

Author

Kalincik, T., Malpas, C. B., Sharmin, S., Izanne Roos, Patti, F., Butzkueven, H., Alroughani, R., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Hupperts, R., Lechner-Scott, J., Sola, P., Ferraro, D., Grammond, P., Csepany, T., Grand Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Wijmeersch, B., Granella, F., Sa, M. J., Bergamaschi, R., Slee, M., Boz, C., Ozakbas, S., Terzi, M., Prevost, J., Solaro, C., Macdonell, R., Cartechini, E., Coles, A., Havrdova, E. K., and Horakova, D.

Published
2019

18. Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

Author

Sharmin, S., Lefort, M., Andersen, J., Horakova, D., Havrdova, E. K., Alroughani, R., Izquierdo, G., Eichau, S., Ozakbas, S., Butzkueven, H., Patti, F., Onofrj, M., Lugaresi, A., Terzi, M., Grammond, P., Grand Maison, F., Yamout, B., Prat, A., Girard, M., Duquette, P., Boz, C., Trojano, M., Mccombe, P., Slee, M., Lechner-Scott, J., Recai Turkoglu, Sola, P., Ferraro, D., Granella, F., Shaygannejad, V., Prevost, J., Skibina, O., Solaro, C., Karabudak, R., Wijmeersch, B., Csepany, T., Spitaleri, D., Vucic, S., Leray, E., Sorensen, P. S., Sellebjerg, F., Magyari, M., Vukusic, S., and Kalincik, T.

Published
2019

19. Predicting long-term sustained disability progression in multiple sclerosis

Author

Sharmin, S., Malpas, C., Horakova, D., Havrdova, E. K., Izquierdo, G., Eichau, S., Trojano, M., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grand Maison, F., Grammond, P., Sola, P., Ferraro, D., Terzi, M., Hupperts, R., Alroughani, R., Boz, C., Shaygannejad, V., Pesch, V., Cartechini, E., Kappos, L., Lechner-Scott, J., Bergamaschi, R., Recai Turkoglu, Solaro, C., Ramo-Tello, C., Iuliano, G., Granella, F., Wijmeersch, B., Spitaleri, D., Bolanos, R. F., Slee, M., Mccombe, P., Prevost, J., Ampapa, R., Ozakbas, S., Sanchez-Menoyo, J. L., Soysal, A., Vucic, S., Petersen, T., Verheul, F., Butler, E., Hodgkinson, S., Sidhom, Y., Gouider, R., Butzkueven, H., and Kalincik, T.

Published
2019

20. Modifiers of the effectiveness of MS immunotherapies

Author

Kalincik, T., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand Maison, F., Sola, P., Ferraro, D., Shaygannejad, V., Alroughani, R., Hupperts, R., Terzi, M., Boz, C., Lechner-Scott, J., Cartechini, E., Pesch, V., Iuliano, G., Granella, F., Bergamaschi, R., Bolanos, R. F., Spitaleri, D., Slee, M., Vucic, S., Ampapa, R., Mccombe, P., Ramo-Tello, C., Petersen, T., Verheul, F., Prevost, J., Olascoaga, J., Cristiano, E., and Butzkueven, H.

Published
2019

21. Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression

Author

Brouwer, E., Peeters, L., Becker, T., Altintas, A., Soysal, A., Wijmeersch, B., Boz, C., Oreja-Guevara, C., Gobbi, C., Solaro, C., Ramo, C., Spitaleri, D. L., Maimone, D., Aguera-Morales, E., Cartechini, E., Butler, E., Havrdova, E., Patti, F., Granella, F., Grand Maison, F., Moore, F., Verheul, F., Iuliano, G., Butzkueven, H., Lechner-Scott, J., Kuhle, J., Sanchez Menoyo, J. L., Rojas, J. I., Prevost, J., Onofrj, M., Rio, M. E., Sa, M. J., Saladino, M. L., Slee, M., Barnett, M., Terzi, M., Deri, N., Mccombe, P., Sola, P., Duquette, P., Grammond, P., Ampapa, R., Alroughani, R., Hupperts, R., Recai Turkoglu, Gouider, R., Fernandez Bolanos, R., Bergamaschi, R., Kalincik, T., and Moreau, Y.

Published
2019

22. Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis

Author

Le, M. V. H., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Ozakbas, S., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Alroughani, R., Bergamaschi, R., Sola, P., Grammond, P., Grand Maison, F., Terzi, M., Boz, C., Hupperts, R., Butzkueven, H., Walt, A., Pucci, E., Granella, F., Pesch, V., Soysa, A., Yamout, B., Lechner-Scott, J., Spitaleri, D., Ampapa, R., Recai Turkoglu, Iuliano, G., Ramo-Tello, C., Sanchez-Menoyo, J. L., Gouider, R., Shaygannejad, V., Prevost, J., Altintas, A., Fragoso, Y., Mccombe, P., Petersen, T., Slee, M., Barnett, M., Vucic, S., and Kalincik, T.

Published
2018

23. Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

Author

Kalincik, T., Spelman, T., Jokubaitis, V., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Grammond, P., Alroughani, R., Lechner-Scott, J., Prevost, J., Terzi, M., Grand Maison, F., Boz, C., Trojano, M., Wijmeersch, B., Pucci, E., Granella, F., Recai Turkoglu, Sola, P., Ferraro, D., Mccombe, P., Solaro, C., Pesch, V., Ozakbas, S., Slee, M., Spitaleri, D., Sanchez-Menoyo, J. L., Ampapa, R., Hodgkinson, S., Karabudak, R., Vucic, S., and Butzkueven, H.

Published
2017

24. Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis

Author

Merkel, B., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Sola, P., Ferraro, D., Grammond, P., Hupperts, R., Bergamaschi, R., Alroughani, R., Boz, C., Terzi, M., Pucci, E., Pesch, V., Grand Maison, F., Fernandez-Bolanos, R., Lechner-Scott, J., Spitaleri, D., Shaygannejad, V., Iuliano, G., Granella, F., Solaro, C., Prevost, J., Petersen, T., Olascoaga, J., Cristina Ramo-Tello, Verheul, F., Mccombe, P., Slee, M., Sanchez-Menoyo, J. L., Cristiano, E., Ozakbas, S., Saladino, M. L., Ampapa, R., Vucic, S., Moore, F., Deri, N., Alkhaboori, J., Barnett, M., Walt, A., Butzkueven, H., and Kalincik, T.

Published
2017

25. Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years

Author

Kalincik, T., Spelman, T., Jokubaitis, V., Horakova, D., Havrdova, E., Trojano, M., Sola, P., Ferraro, D., Lugaresi, A., Izquierdo, G., Alroughani, R., Boz, C., Granella, F., Bergamaschi, R., Grammond, P., Hupperts, R., Grand Maison, F., Prat, A., Girard, M., Duquette, P., Spitaleri, D., Terzi, M., Pesch, V., Ampapa, R., Pucci, E., Iuliano, G., Fernandez-Bolanos, R., Verheul, F., Lechner-Scott, J., Olascoaga, J., Slee, M., Sanchez-Menoyo, J. L., Vucic, S., Prevost, J., Moore, F., Walt, A., Shaygannejad, V., Petkovska-Boskova, T., Ramo-Tello, C., and Butzkueven, H.

Published
2017

26. Evaluation of common criteria of progression of disability in a large observational cohort

Author

Kalincik, T., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., Lugaresi, A., Grand Maison, F., Grammond, P., Hupperts, R., Eva Kubala Havrdova, Pucci, E., Boz, C., Bergamaschi, R., Lechner-Scott, J., Alroughani, R., Pesch, V., Iuliano, G., Rio, M., Fernandez-Bolanos, R., Ramo, C., Terzi, M., Petersen, T., Slee, M., Spitaleri, D., Amato, M. P., Verheul, F., Cristiano, E., Sanchez-Menoyo, J., Fiol, M., Gray, O., Cabrera-Gomez, J., Hodgkinson, S., Barnett, M., Saladino, M., Vucic, S., Shaw, C., Moore, F., Munster, E., Rozsa, C., Mccombe, P., Butzkueven, H., T. Kalincik, V. Jokubaiti, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, G. Izquierdo, M. Girard, P. Duquette, A. Lugaresi, F. Grand’Maison, P. Grammond, R. Huppert, C. Oreja-Guevara, E. Pucci, C. Boz, R. Bergamaschi, J. Lechner-Scott, L. Alroughani, V.Van Pesch, G. Iuliano, M. Rio, R. Fernande-Bolano, C. Ramo, M. Terzi, T. Petersen, M. Slee, D. Spitalieri, MP Amato, F Verheul, E. Cristiano, J. Sanchez-Menoyo, M. Fiol, O. Gray, JA. Cabrera-Gomez, S. Hodgkinson, M. Barnett, M. Saladino, S. Vucic, C. Shaw, F. Moore, E Van Muster, C. Rozsa, P. McCombe, and H. Butzkueven

Subjects
multiple sclerosis, clinical course, progression, clinical evaluation, prognostic factors
Published
2014

27. Comparative efficacy of switch to natalizumab of fingolimod in active relapsing.remitting multiple sclerosis

Author

Kalincik, T., Horakova, D., Spelman, T., Jokubaitis, V., Trojano, M., Lugaresi, A., Izquierdo, G., Rozsa, C., Grammond, P., Alroughani, R., Duquette, P., Girard, M., Pucci, E., Lechner-Scott, J., Mark Slee, Fernandez-Bolanos, R., Grand Maison, F., Hupperts, R., Verheul, F., Hodgkinson, S., Oreja-Guevara, C., Spitaleri, D., Barnett, M., Terzi, M., Bergamaschi, R., Mccombe, P., Sanchez-Menoyo, J., Simo, M., Csepany, T., Rum, G., Boz, C., Havrdova, E., Butzkueven, H., Sbase Study Grp, M., T. Kalincik, D. Horakova, T. Spelman, V. Jokubaiti, M. Trojano, A. Lugaresi, G. Izquierdo, C. Rozsa, P.Grammond, R. Alroughani, P. Duquette, M. Girard, E. Pucci, J. Lechner-Scott, M. Slee, R. Fernandez-Bolano, F. Grand’Maison, R. Huppert, F. Verheul, S. Hodgkinson, C. Oreja-Guevara, D. Spitalieri, M. Barnett, M. Terzi, R. Bergamaschi, P. McCombe, J. Sanchez- Menoyo, M. Simo, T. Csepany, G. Rum, C. Boz, E. Havrdova, H. Butzkueven, and Ms Base Study Group.

Subjects
Multiple sclerosis, fingolimod, natalizumab, treatment
Published
2014

29. Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis

Author

Jokubaitis, V. G., Havrdova, E., Horakova, D., Izquierdo, G., Kalincik, T., Walt, A., Nguyen, A. -L, Terzi, M., Alroughani, R., Duquette, P., Girard, M., Prat, A., Boz, C., Sola, P., Lugaresi, A., Lechner-Scott, J., Barnett, M., Grand Maison, F., Grammond, P., Ramo, C., Turkoglu, R., Mccombe, P., Hupperts, R., Bolanos, R. Fernandez, Pucci, E., Trojano, M., Granella, F., Spitaleri, D., Pesch, V., Soysal, A., Eva Kubala Havrdova, Verheul, F., Vucic, S., Hodgkinson, S., Slee, M., Ampapa, R., Prevost, J., Menoyo, J. L. Sanchez, Skibina, O., Iuliano, G., Solaro, C., Olascoaga, J., Shaw, C., Madsen, K., Naidoo, K., Hyde, R., and Butzkueven, H.

30. The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis

Author

Brown, J. W. L., Lugaresi, A., Horakova, D., Havrdova, E., Jokubaitis, V., Lechner-Scott, J., Trojano, M., Min, M., Shaw, C., Shuey, N., Slee, M., Mccombe, P., Pesch, V., Wijmeersch, B., Prevost, J., Moore, F., Prat, A., Girard, M., Duquette, P., Ayrignac, X., Sempere, A. Perez, Sanchez-Menoyo, J. L., Cristina Ramo-Tello, Csepany, T., Hutchinson, M., Luca, G., Bergamaschi, R., Granella, F., Curti, E., Tsantes, E., Sola, P., Ferraro, D., Alroughani, R., Hupperts, R., Al-Harbi, T., Sidhom, Y., Boz, C., Terzi, M., Ozakbas, S., Soysal, A., Pucci, E., Izquierdo, G., Iuliano, G., Rio, M. Edite, Spitaleri, D., Grammond, P., Grand Maison, F., Butzkueven, H., and Kalincik, T.

31. Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Author

Kunchok, A., Malpas, C., Horakova, D., Havrdova, E., Alroughani, R., Terzi, M., Yamout, B., Karabudak, R., Boz, C., Ozakbas, S., Olascoagam, J., Simon, M., Granellau, F., Mccombe, P., Csepanym, T., Bergamaschi, R., Fragoso, Y., Al-Harbin, T., Recai Turkoglu, Lechner-Scott, J., Laureys, G., Pucci, E., Sola, P., Ferraro, D., Altintas, A., Grand Maison, F., Izquierdo, G., Eichau, S., Lugaresi, A., Marriott, M., Kister, I., Butzkueven, H., and Kalincik, T.

32. Determinants of MS re-activation after discontinuing therapies

Author

Husin, H., Wallace, J., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. Kubala, Izquierdo, G., Eichau, S., Prat, A., Girard, M., Duquette, P., Trojano, M., Grammond, P., Lugaresi, A., Onofrj, M., Ozakbas, S., Butzkueven, H., Sola, P., Ferraro, D., Alroughani, R., Grand Maison, F., Terzi, M., Lechner-Scott, J., Boz, C., Hupperts, R., Shaygannejad, V., Bergamaschi, R., Pucci, E., Pesch, V., Hodgkinson, S., Mccombe, P., Granella, F., Slee, M., Wijmeersch, B., Karabudak, R., Prevost, J., Petersen, T., Spitaleri, D., Barnett, M., Solaro, C., Iuliano, G., Verheul, F., Ramo-Tello, C., Recai Turkoglu, Fernandez Bolanos, R., Butler, E., Macdonell, R., Soysal, A., Betancur, M. Moreno, and Kalincik, T.

34. Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models

Author

Diouf, I., Malpas, C., Sharmin, S., Izanne Roos, Horakova, D., Havrdova, E. K., Patti, F., Shaygannejad, V., Ozakbas, S., Izquierdo, G., Eichau, S., Onofrj, M., Lugaresi, A., Alroughani, R., Duquette, P., Terzi, M., Boz, C., Grand Maison, F., Hamdy, S., Sola, P., Grammond, P., Turkoglu, R., Skibina, O., Buzzard, K., Yamout, B., Altintas, A., Gerlach, O., Pesch, V., Blanco, Y., Maimone, D., Lechner-Scott, J., Bergamaschi, R., Karabudak, R., Barnet, M., Hughes, S., Sa, M. J., Kappos, L., Hodgkinson, S., Butzkueven, H., Prevost, J., Laureys, G., Moore, F., and Kalincik, T.

35. 10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

Author

Jokubaitis, V. G., Spelman, T., Kalincik, T., Travaglini, D., Paolicelli, D., Duquette, P., Girard, M., Prat, A., Havrdova, E., Horakova, D., Izquierdo, G., Grammond, P., Pucci, E., Grand Maison, F., Bergamaschi, R., Granella, F., Pesch, V., Hupperts, R., Iuliano, G., Spitaleri, D., Sola, P., Boz, C., Fernandez-Bolanos, R., Petersen, T., Verheul, F., Olascoaga, J., Pamela Ann McCombe, Rozsa, C., Lechner-Scott, J., Terzi, M., Hodgkinson, S., Ramo, C., Saladino, M. L., Butzkueven, H., Lugaresi, A., Trojano, M., and MSBase Study Grp

36. Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis

Author

Izanne Roos, Malpas, C., Leray, E., Casey, R., Horakova, D., Havrdova, E. Kubala, Debouverie, M., Patti, F., Seze, J., Izquierdo, G., Eichau, S., Edan, G., Prat, A., Girard, M., Ozakbas, S., Grammond, P., Zephir, H., Ciron, J., Maillart, E., Moreau, T., Amato, M. P., Labauge, P., Alroughani, R., Buzzard, K., Skibina, O., Terzi, M., Laplaud, D., Berger, E., Grand Maison, F., Lebrun-Frenay, C., Cartechini, E., Boz, C., Lechner-Scott, J., Clavelou, P., Stankoff, B., Prevost, J., Kappos, L., Pelletier, J., Shaygannejad, V., Yamout, B., Gerlach, O., Spitaleri, D., Pesch, V., Gout, O., Turkoglu, R., Heinzlef, O., Thouvenot, E., Vukusic, S., Butzkueven, H., and Kalincik, T.

37. Aggressive form of multiple sclerosis can be predicted early after disease onset

Author

Malpas, C. B., Manouchehrinia, A., Sharmin, S., Izanne Roos, Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand Maison, F., Ozakbas, S., Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H., Soysal, A., Petersen, T., Verheul, F., Karabudak, R., Turkoglu, R., Ramo-Tello, C., Terzi, M., Cristiano, E., Slee, M., Mccombe, P., Macdonell, R., Fragoso, Y., Olascoaga, J., Altintas, A., Olsson, T., Hillert, J., and Kalincik, T.

38. Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide

Author

Spelman, T., Tomas Kalincik, Trojano, M., Grand Maison, F., Izquierdo, G., Havrdova, E., Dana Horakova, Lugaresi, A., Duquette, P., Grammond, P., Hupperts, R., Jeannette Lechner-Scott, Granella, F., Petersen, T., Terzi, M., Eugenio Pucci, Patrizia Sola, Pesch, V., Iuliano, G., Oreja-Guevara, C., Cavit Boz, Bergamaschi, R., Mark Slee, and Helmut Butzkueven

39. Determinants of therapeutic lag in relapsing multiple sclerosis

Author

Izanne Roos, Frascoli, F., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Patti, F., Prat, A., Girard, M., Duquette, P., Onofr, M., Lugaresi, A., Grammond, P., Ozakbas, S., Sola, P., Ferraro, D., Bergamaschi, R., Cartechini, E., Sa, M. J., Boz, C., Grand Maison, F., Lechner-Scott, J., Terzi, M., Granella, F., Alroughani, R., Iuliano, G., Hupperts, R., Spitaleri, D., Pesch, V., Soysal, A., Prevost, J., Olascoaga, J., Aguera-Morales, E., Turkoglu, R., Slee, M., Ramo-Tello, C., Sidhom, Y., Gouider, R., Mccombe, P., Butzkueven, H., Malpas, C., and Kalincik, T.

41. Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis

Author

Lorscheider, J., Jokubaitis, V., Spelman, T., Izquierdo, G., Lugaresi, A., Havrdova, E., Horakova, D., Trojano, M., Duquette, P., Girard, M., Prat, A., Grand Maison, F., Hupperts, R., Grammond, P., Pucci, E., Boz, C., Sola, P., Spitaleri, D., Lechner-Scott, J., Terzi, M., Pesch, V., Iuliano, G., Bergamaschi, R., Bolanos, R. F., Ramo-Tello, C., Granella, F., Rio, M. E., Eva Kubala Havrdova, Butzkueven, H., Kalincik, T., and Sbase Study Grp, M.

42. Risk of secondary progressive multiple sclerosis: a longitudinal study

Author

Fambiatos, A., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Izquierdo, G., Grand Maison, F., Grammond, P., Sola, P., Ferraro, D., Alroughani, R., Terzi, M., Hupperts, R., Boz, C., Lechner-Scott, J., Pucci, E., Bergamaschi, R., Pesch, V., Ozakbas, S., Granella, F., Ramo, C., Recai Turkoglu, Iuliano, G., Spitaleri, D., Mccombe, P., Solaro, C., Slee, M., Fernandez-Bolanos, R., Ampapa, R., Soysal, A., Petersen, T., Sanchez-Menoyo, J. L., Verheul, F., Prevost, J., Sidhom, Y., Gouider, R., Wijmeersch, B., Vucic, S., Cristiano, E., Saladino, M. L., Deri, N., Barnett, M., Walt, A., Butzkueven, H., and Kalincik, T.

43. Disability accrual in primary-progressive & secondary-progressive multiple sclerosis

Author

Harding-Forrester, S., Izanne Roos, Sharmin, S., Diouf, I., Malpas, C., Nguyen, A. -L, Moradi, N., Horakova, D., Havrdova, E. Kubala, Patti, F., Izquierdo, G., Eichau, S., Prat, A., Girard, M., Duquette, P., Onofrj, M., Lugaresi, A., Grand Maison, F., Weinstock-Guttman, B., Amato, M. P., Grammond, P., Gerlach, O., Ozakbas, S., Sola, P., Ferraro, D., Butzkueven, H., Lechner-Scott, J., Boz, C., Alroughani, R., Pesch, V., Cartechini, E., Terzi, M., Maimone, D., Ramo-Tello, C., Spitaleri, D., Kappos, L., Yamout, B., Sa, M., Slee, M., Blanco, Y., Bergamaschi, R., Butler, E., Iuliano, G., Granella, F., Sidhom, Y., Gouider, R., Ampapa, R., Wijmeersch, B., Karabudak, R., Prevost, J., Sanchez-Menoyo, J. L., Verheul, F., Mccombe, P., Castillo-Trivino, T., Macdonell, R., Altintas, A., Laureys, G., Hijfte, L., Walt, A., Vucic, S., Turkoglu, R., Barnett, M., Cristiano, E., Zakaria, M., Shaygannejad, V., Hodgkinson, S., Soysal, A., and Kalincik, T.

44. Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis

Author

Izanne Roos, Sharmin, S., Ozakbas, S., Horakova, D., Havrdova, E. K., Boz, C., Alroughani, R., Patti, F., Terzi, M., Lechner-Scott, J., Izquierdo, G., Eichau, S., Grammond, P., Buzzard, K., Skibina, O., Prat, A., Girard, M., Duquette, P., Soysal, A., Grand Maison, F., Kuhle, J., Walt, A., Butzkueven, H., Turkoglu, R., Butler, E., Laureys, G., Hijfte, L., Shaygannejad, V., Yamout, B., Khoury, S., Prevost, J., Sidhom, Y., Gouider, R., Cartechini, E., Sanchez-Menoyo, J. L., Sa, M. Jose, Macdonell, R., Pesch, V., Ramo-Tello, C., Mccombe, P., Willekens, B., Spitaleri, D., Ampapa, R., Al-Asmi, A., Slee, M., Besora, S., Malpas, C., and Kalincik, T.

45. Early clinical predictors of severe MS

Author

Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand Maison, F., Ozakbas, S., Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H., Soysal, A., Petersen, T., Verheul, F., Karabudak, R., Recai Turkoglu, Ramo-Tello, C., Terzi, M., Cristiano, E., Slee, M., Mccombe, P., Macdonell, R., Fragoso, Y., Olascoaga, J., Altintas, A., and Kalincik, T.

46. Multiple Sclerosis Severity Score (MSSS) helps predict relapses and recovery from disability in patients treated for multiple sclerosis in the MSBase model

Author

Kister, I., Bacon, T. E., Malpas, C. B., Sharmin, S., Horakova, D., Havrdova, E. K., Patti, F., Izquierdo, G., Eichau, S., Ozakbas, S., Onofrj, M., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Sola, P., Ferraro, D., Alroughani, R., Terzi, M., Boz, C., Grand Maison, F., Bergamaschi, R., Hupperts, R., Sa, M. J., Kappos, L., Cartechini, E., Lechner-Scott, J., Pesch, V., Shaygannejad, V., Granella, F., Spitaleri, D., Iuliano, G., Maimone, D., Prevost, J., Soysal, A., Recai Turkoglu, Ampapa, R., Butzkueven, H., and Kalincik, T.

47. Risk of early relapse following switch to oral agents for multiple sclerosis

Author

Spelman, T., Mekhael, L., Burke, T., Butzkueven, H., Hodgkinson, S., Havrdova, E., Horakova, D., Duquette, P., Izquierdo, G., Grand Maison, F., Grammond, P., Barnett, M., Lechner-Scott, J., Alroughani, R., Trojano, M., Lugaresi, A., Granella, F., Pucci, E., Vucic, S., and Sbase Study Grp, M.

48. Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis

Author

Kalincik, T., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Lechner-Scott, J., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Solaro, C., Grand Maison, F., Hupperts, R., Prevost, J., Sola, P., Ferraro, D., Terzi, M., Butler, E., Slee, M., Allan Kermode, Fabis-Pedrini, M., Mccombe, P., Barnett, M., Shaw, C., Hodgkinson, S., and Butzkueven, H.

49. Comparative analysis of MS outcomes in natalizumab-treated patients using a novel three-way multinomial propensity score match

Author

Spelman, T., Pellegrini, F., Zhang, A., Trojano, M., Wiendl, H., Kappos, L., Hyde, R., Koendgen, H., Verheul, F., Grand Maison, F., Izquierdo, G., Havrdova, E., Horakova, D., Lugaresi, A., Duquette, P., Grammond, P., Hupperts, R., Lechner-Scott, J., Granella, F., Petersen, T., Terzi, M., Pucci, E., Sola, P., Butzkueven, H., MSBase Study Grp, and Tysabri Observational Programme In

50. Individual response to disease modifying therapies: a global observational cohort study

Author

Kalincik, T., Sobisek, L., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Girard, M., Prat, A., Duquette, P., Grammond, P., Sola, P., Hupperts, R., Grand Maison, F., Pucci, E., Boz, C., Alroughani, R., Pesch, V., Lechner-Scott, J., Terzi, M., Bergamaschi, R., Iuliano, G., Granella, F., Spitaleri, D., Shaygannejad, V., Eva Kubala Havrdova, Slee, M., Ampapa, R., Verheul, F., Mccombe, P., Olascoaga, J., Amato, M. P., Vucic, S., Hodgkinson, S., Ramo, C., Flechter, S., Cristiano, E., Rozsa, C., Moore, F., Sanchez-Menoyo, J. L., Saladino, M. L., Barnett, M., Butzkueven, H., and Sbase Study Grp, M.

Catalog

Books, media, physical & digital resources
See catalog results